The first mRNA flu shot is now available. Here’s who can get it.
Moderna's first mRNA flu vaccine has received FDA approval and is now available for older adults ahead of the 2026 flu season.
14 trends tracked about this subject — the full history, oldest to newest below.
Moderna's first mRNA flu vaccine has received FDA approval and is now available for older adults ahead of the 2026 flu season.
Moderna and Merck trial data sparks debate over whether a personalized medicine revolution is beginning.
Health coverage highlights FDA approval of Moderna's new mRNA flu vaccine and emerging studies on broader antibody responses.
Recent studies link the shingles vaccine to significant reductions in dementia and cardiovascular disease risks.
The FDA has approved Moderna's mRNA-based flu vaccine, marking a shift in immunization technology for older adults.
Recent trial results for an mRNA vaccine developed by Moderna point toward a potential shift in future cancer care.
Moderna shares double following clinical trial results for a personalized mRNA melanoma vaccine developed with Merck.
Merck and Moderna’s melanoma vaccine hits key survival milestones, sending Moderna's stock soaring.
Moderna stock surges after a partnered melanoma vaccine developed with Merck successfully reduced cancer recurrence in a large-scale clinical trial.
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
1 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
The first mRNA-based flu vaccine has been approved in the US, specifically targeting adults aged 50 and over for improved effectiveness.
3 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
The U.S. has approved the first-ever mRNA flu vaccine from Moderna, though concerns over side effects may impact public adoption.